RISK OF SERIOUS INFECTIONS ASSOCIATED WITH VEDOLIZUMAB VERSUS TUMOR NECROSIS FACTOR ANTAGONISTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A MULTINATIONAL, POPULATION-BASED COHORT STUDY

Julien Kirchgesner  1     Rishi J Desai  1     Laurent Beaugerie  2     Sebastian Schneeweiss  1     Seoyoung C Kim  3    
1 Brigham and Women's Hospital and Harvard Medical School,Boston,United States
2 Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique,Paris,France
3 B

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing